EMEA-002197-PIP01-17
Key facts
| Active substance |
Soluble human T cell receptor (TCR) directed against the glycoprotein 100 (gp100) melanoma antigen, linked to the single-chain variable fragment (ScFv) domain of the anti-cluster of differentiation 3 (CD3) antibody
|
| Therapeutic area |
Oncology
|
| Decision number |
EMEA-002197-PIP01-17
|
| PIP number |
EMEA-002197-PIP01-17
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of ocular melanoma
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Immunocore Ltd
Tel. +1 2153139618
E-mail: Chris.Coughlin@immunocore.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|